Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1954 1
1955 1
1959 1
1962 1
1963 1
1964 2
1965 4
1966 11
1967 3
1968 4
1969 4
1970 3
1971 5
1972 1
1973 1
1974 6
1975 7
1976 6
1977 7
1978 6
1979 9
1980 5
1981 13
1982 8
1983 7
1984 10
1985 10
1986 14
1987 22
1988 7
1989 16
1990 21
1991 16
1992 22
1993 25
1994 28
1995 25
1996 30
1997 23
1998 26
1999 35
2000 36
2001 36
2002 37
2003 40
2004 40
2005 55
2006 49
2007 48
2008 76
2009 82
2010 57
2011 76
2012 75
2013 76
2014 80
2015 75
2016 68
2017 72
2018 89
2019 91
2020 112
2021 111
2022 95
2023 99
2024 78
2025 86
2026 62

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,119 results

Results by year

Filters applied: . Clear all
Page 1
Inebilizumab for Treatment of IgG4-Related Disease.
Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, Löhr JM, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Wallace ZS, Ebbo M, Webster GJ, Martinez Valle F, Nayar MK, Perugino CA, Rebours V, Dong X, Wu Y, Li Q, Rampal N, Cimbora D, Culver EL; MITIGATE Trial Investigators. Stone JH, et al. Among authors: okazaki k. N Engl J Med. 2025 Mar 27;392(12):1168-1177. doi: 10.1056/NEJMoa2409712. Epub 2024 Nov 14. N Engl J Med. 2025. PMID: 39541094 Clinical Trial.
The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD.
Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S, Ishizaka N, Akamizu T, Sato Y, Kawano M; Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan.. Umehara H, et al. Among authors: okazaki k. Mod Rheumatol. 2021 May;31(3):529-533. doi: 10.1080/14397595.2020.1859710. Epub 2021 Jan 28. Mod Rheumatol. 2021. PMID: 33274670 Free article.
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.
Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. Wallace ZS, et al. Among authors: okazaki k. Ann Rheum Dis. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. Ann Rheum Dis. 2020. PMID: 31796497 Review.
Randomized Controlled Trial of High-Flow Nasal Cannula in Preterm Infants After Extubation.
Uchiyama A, Okazaki K, Kondo M, Oka S, Motojima Y, Namba F, Nagano N, Yoshikawa K, Kayama K, Kobayashi A, Soeno Y, Numata O, Suenaga H, Imai K, Maruyama H, Fujinaga H, Furuya H, Ito Y; NON-INVASIVE PROCEDURE FOR PREMATURE NEONATES (NIPPN) STUDY GROUP. Uchiyama A, et al. Among authors: okazaki k. Pediatrics. 2020 Dec;146(6):e20201101. doi: 10.1542/peds.2020-1101. Pediatrics. 2020. PMID: 33214331 Clinical Trial.
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia.
Ochi Y, Liew-Littorin M, Nannya Y, Bengtzen S, Piauger B, Deneberg S, Jädersten M, Lazarevic V, Cammenga J, Robelius A, Wennström L, Ölander E, Kasahara S, Hiramoto N, Kanemura N, Sezaki N, Sakurada M, Iwasaki M, Kanda J, Ueda Y, Yoshihara S, Erkers T, Struyf N, Watanabe Y, Motomura M, Nakagawa MM, Saiki R, Fukushima H, Okazaki K, Morimoto S, Yoda A, Okuda R, Komatsu S, Xie G, Österroos A, Kon A, Zhao L, Shiraishi Y, Ishikawa T, Miyano S, Katayama K, Imoto S, Matsuda S, Takaori-Kondo A, Aburatani H, Suzuki HI, Kallioniemi O, Juliusson G, Höglund M, Lehmann S, Ogawa S. Ochi Y, et al. Among authors: okazaki k. Nature. 2026 Aug;656(8128):752-762. doi: 10.1038/s41586-026-10703-4. Epub 2026 Jul 8. Nature. 2026. PMID: 42420449 Free PMC article.
Obexelimab for the Treatment of IgG4-Related Disease.
Della-Torre E, Baker MC, Zhang W, Perugino CA, Katz G, Tanaka Y, Khosroshahi A, Kleger A, Schleinitz N, Martinez-Valle F, Schulze-Koops H, Nakayamada S, Rebours V, Okazaki K, Dong L, Carruthers M, Chen LYC, Frulloni L, Meysami A, Takahashi H, Kawano M, Liu Y, Saeki T, Ebbo M, Alexander T, González García A, Karadag O, Maślińska M, Quinn SM, Poma A, Wells A, Greene TJ, Stone JH, Culver EL; INDIGO Trial Investigators. Della-Torre E, et al. Among authors: okazaki k. N Engl J Med. 2026 Jun 2. doi: 10.1056/NEJMoa2601337. Online ahead of print. N Engl J Med. 2026. PMID: 42233621
Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020.
Okazaki K, Kawa S, Kamisawa T, Ikeura T, Itoi T, Ito T, Inui K, Irisawa A, Uchida K, Ohara H, Kubota K, Kodama Y, Shimizu K, Tonozuka R, Nakazawa T, Nishino T, Notohara K, Fujinaga Y, Masamune A, Yamamoto H, Watanabe T, Nishiyama T, Kawano M, Shiratori K, Shimosegawa T, Takeyama Y; Members of the Research Committee for IgG4-related Disease supported by the Ministry of Health, Labour, Welfare of Japan, Japan Pancreas Society. Okazaki K, et al. J Gastroenterol. 2022 Apr;57(4):225-245. doi: 10.1007/s00535-022-01857-9. Epub 2022 Feb 22. J Gastroenterol. 2022. PMID: 35192048 Free PMC article. Review.
2,119 results